al, on a group of quinoline-3-carboxamide drugs, known for reducing inflammation and symptoms of autoimmune disease, led to the discovery of binding by S100A9 to TLR4 as a main target of these drugs (20). This evidence concerns the gene S100A9 and autoimmune disease.